Saturday, July 11, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 12 of 25
  1. Arvisol placebo, Arvisol 150mg

    Pari Pharma GmbH

    Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

    phase 2 small molecule active

    1 trial
  2. BFB759, Placebo

    Blue Earth Diagnostics Ireland Ltd

    Atopic dermatitis

    phase 2 small molecule active

    1 trial
  3. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial
  4. BMS-945429 Placebo

    CSL Behring GmbH

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial
  5. Bexarotene/NBUVB vs placebo NBUVB

    LIGAND PHARMACEUTICALS INC

    Psoriasis

    phase 2 small molecule completed

    1 trial
  6. Budenofalk 4 mg Zäpfchen, placebo to test

    Dr. Falk Pharma GmbH

    Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

    phase 2 small molecule active

    1 trial
  7. CRD-4730, CRD-4730 matching placebo

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial
  8. Crofelemer Placebo Powder for Oral Solution

    Lacuna Pharma Pty Ltd

    Microvillous Inclusion Disease (MVID)

    phase 2 small molecule active

    1 trial
  9. DASATINIB, Placebo

    The George Institute

    Asymptomatic patients with recent HIV-1 infection

    phase 2 small molecule active

    1 trial
  10. DNTH103, Matching placebo to DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial
  11. EB01 Cream Placebo

    Edesa Biotech

    Allergic Contact Dermatitis

    phase 2 small molecule completed

    1 trial
  12. EDP-938, EDP-938 Placebo tablets

    ENANTA PHARMACEUTICALS INC

    Respiratory syncytial virus (RSV)

    phase 2 small molecule active

    1 trial
  13. Enpatoran Placebo, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial
  14. Fasedienol Nasal Spray - Placebo Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 2 small molecule active

    1 trial
  15. Film-coated placebo to match estetrol monohydrate (E4) 20mg tablet

    Estetra SPRL

    postmenopausal women with vasomotor menopausal symptoms

    phase 2 small molecule active

    1 trial
  16. Flortaucipir, Placebo to match LY3372689

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial
  17. Frexalimab, Matched Placebo for Test

    Sanofi-aventis Healthcare Pty Ltd

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial
  18. GS-4321 PLACEBO

    Gilead Sciences Pty Limited

    Chronic Hepatitis Delta.

    phase 2 small molecule active

    1 trial
  19. IDOR-1117-2520 matching placebo

    Lacuna Pharma Pty Ltd

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial
  20. ILT-101 liquide, Placebo of ILT-101

    Pari Pharma GmbH

    Autism Spectrum disorder ASD

    phase 2 small molecule active

    1 trial
  21. INCB000928, Placebo

    Incyte

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial
  22. IPN10200, IPN10200 placebo

    Ipsen

    Episodic Migraine Chronic Migraine

    phase 2 small molecule active

    1 trial
  23. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia, Familial

    phase 2 small molecule completed

    1 trial
  24. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    2 trials

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.